ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1666

The Relevance of Urinary Podocyte Number and Urinary Podocalyxin Level with Response to Treatment and 1 Year Renal Prognosis in Systemic Lupus Erythematosus

Hiroshi Kajiyama1, Keiju Hiromura2, Daisuke Ikuma1, Hidekazu Ikeuchi2, Hiroyuki Kurosawa3, Yoshiaki Hirayama3, Fumio Gondaira3, Masanori Hara4, Yoshihisa Nojima2 and Toshihide Mimura5, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 2Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 3Department of reagent research and development, Denka Seiken Co. Ltd., Niigata, Japan, 4Department of Pediatrics, Yoshida Hospital, Niigata, Japan, 5Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biomarkers, Lupus nephritis, prognostic factors, systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose

Podocytes are glomerular visceral epithelial cells, whose number decrease due to death and/or detachment from capillary wall leads to severe proteinuria and end stage kidney disease. Podocalyxin (PCX) is one of the podocyte markers, and we reported in ACR meeting last year that two different urine PCX-related biomarkers, urine numbers of PCX-positive cells (podocytes, U-Pod) and urine levels of PCX (U-PCX) were higher in systemic lupus erythematosus (SLE) patients with kidney disease (KD) than those without KD. Purpose of this longitudinal study is to clarify the relevance of U-Pod and U-PCX with the response to treatment and renal prognosis.

Methods

U-Pod were determined by counting PCX-positive cells in sediments from urine samples. U-PCX were measured by sandwich ELISA, normalized to urine creatinine levels. Patients with proteinuria (defined as more than 0.2 urine protein/creatinine ratio, U-PCR) and/or renal failure (defined as estimated glomerular filtration rate, eGFR, less than 60 mL/min/1.73m2) were defined as KD(+), and other patients were defined as KD(-). Patients were recruited between October 2010 and March 2013, 18 SLE-KD(+) patients (ISN/RPS Classification, IV: 5 patients, IV+V: 2 patients, V: 2 patients, biopsy was not performed in 9 patients), and 11 SLE-KD(-) patients. U-Pod, U-PCX, U-PCR and eGFR were obtained around the treatment start, and at 1, 3, 6 and 12 months (mo) after treatment. Correlation of cumulative U-Pods generated by the summations of U-Pods in first 6 months with one year change of eGFR was determined. Statistical analysis was done with Wilcoxon signed-rank test and Spearman correlation. p<0.05 was defined as statistical significance. Each value was described as median and interquartile range.

Results

In KD(-), U-Pod, U-PCX, and U-PCR were not significantly changed all through the year. In KD(+), U-PCR was significantly improved from 6 mo after treatment (before treatment 2.86 (0.91, 5.16), vs 1 mo 1.15 (0.42, 3.99) p=0.2366, vs 3 mo 0.41 (0.21, 3.80) p=0.0894, vs 6 mo 0.31 (0.11, 0.95) p=0.0004, vs 12 mo 0.22 (0.08, 0.72) p=0.0061). U-Pod significantly improved at 1 mo after treatment (before treatment 1.65 (0, 6.07), vs 1 mo 0.30 (0, 1.48) p=0.0084, vs 3 mo 0.30 (0, 0.60) p=0.0046, vs 6 mo 0 (0, 0.45) p=0.0037, vs 12 mo 0 (0, 0.25) cells/mL p=0.0039). Interestingly, U-PCX improvement delayed significantly, and was observed from 6 mo (before treatment 360.0 (160.0, 586.8), vs 1 mo 363.5 (185.5, 540.8) p=0.4204, vs 3 mo 294.0 (114.0, 422.5) p=0.072, vs 6 mo 154.9 (65.5, 251.5) p=0.0039, vs 12 mo 66.6 (41.5, 178.3) μg/gCr p=0.0008). One year changes of eGFR (subtracting 12 mo eGFR from pre-treatment eGFR) were -2.067 (-10.59, 16.00) mL/min./1.73m2 in KD(+) and -20.61 (-35.75, 1.002) mL/min./1.73m2in KD(-). There was no significant correlation of cumulative U-Pods with one year change of eGFR both in KD(+) and KD(-) (p=0.7228, and p=0.3831).

Conclusion

U-Pod significantly improves one month after treatment much faster than U-PCR and U-PCX, suggesting that U-Pod reflects acute inflammation, and that U-PCX is more relevant to filter dysfunction of podocyte. Cumulative podocyte loss may not affect decline of eGFR in one year in SLE.


Disclosure:

H. Kajiyama,
None;

K. Hiromura,
None;

D. Ikuma,
None;

H. Ikeuchi,
None;

H. Kurosawa,
None;

Y. Hirayama,
None;

F. Gondaira,
None;

M. Hara,
None;

Y. Nojima,
None;

T. Mimura,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relevance-of-urinary-podocyte-number-and-urinary-podocalyxin-level-with-response-to-treatment-and-1-year-renal-prognosis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology